Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management

Open access
Pennisi, Martina, Jain, Tania, Santomasso, Bianca D., Mead, Elena, Wudhikarn, Kitsada, Silverberg, Mari Lynne, Batlevi, Yakup, Shouval, Roni, Devlin, Sean M., Batlevi, Connie, Brentjens, Renier J., Dahi, Parastoo B., Diamonte, Claudia, Giralt, Sergio, Halton, Elizabeth F., Maloy, Molly, Palomba, Maria Lia, Sanchez-Escamilla, Miriam, Sauter, Craig S., Scordo, Michael, Shah, Gunjan, Park, Jae H., Perales, Miguel-Angel · 2020 · Blood Advances

Abstract

Various grading systems are currently used for chimeric antigen receptor (CAR) T-cell–related toxicity, cytokine release syndrome (CRS), and immune effector cell–associated neurotoxicity syndrome (ICANS). We compared the recently proposed American Society for Transplantation and Cellular Therapy (ASTCT) grading system to other grading scores in 2 populations of adults: patients (n = 53) with B-cell acute lymphoblastic leukemia (B-ALL) treated with 1928z CAR T-cells (clinicaltrials.gov #NCT01044069), and patients (n = 49) with diffuse large B-cell lymphoma (DLBCL) treated with axicabtagene-ciloleucel (axi-cel) or tisagenlecleucel after US Food and Drug Administration approval. According to ASTCT grading, 82% of patients had CRS, 87% in the B-ALL and 77% in the DLBCL groups (axi-cel: 86%, tisagenlecleucel: 54%), whereas 50% of patients experienced ICANS, 55% in the B-ALL and 45% in the DLBCL groups (axi-cel: 55%, tisagenlecleucel: 15%). All grading systems agreed on CRS and ICANS diagnosis in 99% and 91% of cases, respectively. However, when analyzed grade by grade, only 25% and 54% of patients had the same grade in each system for CRS and ICANS, respectively, as different systems score symptoms differently (upgrading or downgrading their severity), leading to inconsistent final grades. Investigation of possible management implications in DLBCL patients showed that different recommendations on tocilizumab and steroids across current guidelines potentially result in either overtreating or delaying treatment. Moreover, because these guidelines are based on single products and different grading systems, they cannot be universally applied. To avoid discrepancies in assessing and managing toxicities of different products, we propose that unified grading be used across clinical trials and in practice and that paired management guidelines with product-specific indications be developed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000952

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 158

Metadata

Authors
Pennisi, M., Jain, T., Santomasso, B. D., Mead, E., Wudhikarn, K., Silverberg, M. L., Batlevi, Y., Shouval, R., Devlin, S. M., Batlevi, C., Brentjens, R. J., Dahi, P. B., Diamonte, C., Giralt, S., Halton, E. F., Maloy, M., Palomba, M. L., Sanchez-Escamilla, M., Sauter, C. S., Scordo, M., Shah, G., Park, J. H., & Perales, M.-A.
Venue
Blood Advances
Published
2020-02-21
Volume
4
Issue
4
Pages
676-686
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3007888754
Cited by
158
References
9
FWCI
7.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000952
The paper
Pennisi, M., Jain, T., Santomasso, B. D., Mead, E., Wudhikarn, K., Silverberg, M. L., Batlevi, Y., Shouval, R., Devlin, S. M., Batlevi, C., Brentjens, R. J., Dahi, P. B., Diamonte, C., Giralt, S., Halton, E. F., Maloy, M., Palomba, M. L., Sanchez-Escamilla, M., Sauter, C. S., . . . Perales, M.-A. (2020). Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000952

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.